The FDA has granted fast track designation to nadunolimab for use in combination with gemcitabine and nab-paclitaxel to treat patients with previously untreated, metastatic PDAC with high IL1RAP ...

The FDA has accepted the application for lurbinectedin in combination with atezolizumab as first-line maintenance for ES-SCLC.

The Clinical Advisor spoke with Carlos Gutiérrez, EdD, MMS, PA-C, about the impact of executive orders on LGBTQ+ health care.